Latest Conference

Study proves the role of harnessing CrAgSQ for management over the infection.

The impact of remdesivir across age groups.

Customizing treatment strategies for enhanced outcomes and longevity.

Defense against omicron in HIV-positive patients post-COVID.

The therapy, lenacapavir, showed sustained virological suppression and safety over a 2-year period in this treatment-challenged patient population.

Both the use of a vaginal ring or oral pre-exposure prophylaxis were found to be safe for HIV prevention throughout pregnancy.

Insights from CROI on the HepB-CpG vaccine trial.

Biomarkers associated with mortality differed by sex and there may be distinct pathophysiologic mechanisms that account for the increased risk seen in females, according to investigators.

Unraveling monocyte activation and the implications for cardiovascular risk

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.

A National Institutes of Health (NIH) sponsored study reveals a need for more accurate screening in Black people and cisgender women.

Study shows high efficacy of a 4-week glecaprevir/pibrentasvir regimen for shorter, more manageable treatment duration.

In a phase 1 study, the investigational therapy known as cabotegravir ultra long-acting (CAB-ULA), showed positive pharmacokinetic, tolerability, and safety data supporting a prospective move to the next stage of clinical development.

Study presented at CROI 2024 reveals chronic hepatitis B virus (HBV) infection heightens COVID-19 severity as vaccination reduces mortality and ICU demands in co-infected individuals.

Study presented at CROI 2024 reveals that the introduction of Doxycycline post-exposure prophylaxis (doxy-PEP) guidelines in San Francisco has significantly decreased the incidence of chlamydia and syphilis

A new study offers some clues into the pathophysiology and biomarkers of post-acute Sequelae of SARS-CoV-2 (PASC).

From the ongoing CROI meeting, the FDA approved antiretroviral was studied over a 2-year period and showed treatment benefit.

Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.

A clinician discusses the ongoing challenges presented with critically ill patients and the timing and scope of antibiotic prescribing practices.

A study showed the Clostridioides difficile treatment remained effective after subsequent systemic antibiotic exposure.

A study presented at IDWeek details some of the shortfalls in utilization.

Contagion attended IDWeek, and here are some of the top stories we reported on while we were there. Continue to catch our coverage in the days to follow!

A number of factors has led to the increased incidence rates, but questions remain if the vector-borne disease's numbers are being captured accurately.

A Centers for Disease Control and Prevention (CDC) epidemiologist provides insights on a large study.

Natural infection plus COVID-19 vaccination in pregnant mothers conferred more durable antibody responses in infants than natural infection alone.

Heather Yun, MD, FACP, FIDS who is this year’s IDWeek Chair for the Infectious Diseases Society of America (IDSA) talks about the honor of the position, the collective effort to put together the conference, and offers insights on AMR during war, as well as new emerging infectious disease threats.

The findings may support further COVID-19 vaccination in children and reduce vaccine hesitancy.

A late-breaking abstract presented at IDWeek reports on the data around the Prefusion F Protein vaccine.